These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 24622513)

  • 41. Stable mixed chimerism after hematopoietic stem cell transplantation in Wiskott-Aldrich syndrome.
    Doğu F; Kurtuluş-Ulküer M; Bilge Y; Bozdoğan G; Ulküer U; Malhatun E; Ikincioğullari A; Babacan E
    Pediatr Transplant; 2006 May; 10(3):395-9. PubMed ID: 16677369
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Medicine. Gene therapy that works.
    Verma IM
    Science; 2013 Aug; 341(6148):853-5. PubMed ID: 23970689
    [No Abstract]   [Full Text] [Related]  

  • 43. Development of lentiviral gene therapy for Wiskott Aldrich syndrome.
    Galy A; Roncarolo MG; Thrasher AJ
    Expert Opin Biol Ther; 2008 Feb; 8(2):181-90. PubMed ID: 18194074
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome.
    Candotti F
    J Clin Immunol; 2018 Jan; 38(1):13-27. PubMed ID: 29086100
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successful allogeneic hemopoietic stem cell transplantation in a case of Wiskott-Aldrich syndrome and non-Hodgkin lymphoma.
    Tavil B; Erdem AY; Azik F; Isik P; Metin A; Emir S; Uckan D; Tunc B
    Pediatr Transplant; 2013 Sep; 17(6):E146-8. PubMed ID: 23773507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A unique presentation of Wiskott-Aldrich syndrome in relation to platelet size.
    Patel PD; Samanich JM; Mitchell WB; Manwani D
    Pediatr Blood Cancer; 2011 Jul; 56(7):1127-9. PubMed ID: 21488158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Wiskott-Aldrich syndrome: a comprehensive review.
    Massaad MJ; Ramesh N; Geha RS
    Ann N Y Acad Sci; 2013 May; 1285():26-43. PubMed ID: 23527602
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel membrane cell projection defects in Wiskott-Aldrich syndrome B cells.
    Andreu N; Aran JM; Fillat C
    Int J Mol Med; 2007 Oct; 20(4):445-50. PubMed ID: 17786274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. WASP and the phenotypic range associated with deficiency.
    Notarangelo LD; Notarangelo LD; Ochs HD
    Curr Opin Allergy Clin Immunol; 2005 Dec; 5(6):485-90. PubMed ID: 16264326
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gene therapy of primary T cell immunodeficiencies.
    Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
    Gene; 2013 Aug; 525(2):170-3. PubMed ID: 23583799
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.
    Magnani A; Semeraro M; Adam F; Booth C; Dupré L; Morris EC; Gabrion A; Roudaut C; Borgel D; Toubert A; Clave E; Abdo C; Gorochov G; Petermann R; Guiot M; Miyara M; Moshous D; Magrin E; Denis A; Suarez F; Lagresle C; Roche AM; Everett J; Trinquand A; Guisset M; Bayford JX; Hacein-Bey-Abina S; Kauskot A; Elfeky R; Rivat C; Abbas S; Gaspar HB; Macintyre E; Picard C; Bushman FD; Galy A; Fischer A; Six E; Thrasher AJ; Cavazzana M
    Nat Med; 2022 Jan; 28(1):71-80. PubMed ID: 35075289
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Megakaryocyte-specific Profilin1-deficiency alters microtubule stability and causes a Wiskott-Aldrich syndrome-like platelet defect.
    Bender M; Stritt S; Nurden P; van Eeuwijk JM; Zieger B; Kentouche K; Schulze H; Morbach H; Stegner D; Heinze KG; Dütting S; Gupta S; Witke W; Falet H; Fischer A; Hartwig JH; Nieswandt B
    Nat Commun; 2014 Sep; 5():4746. PubMed ID: 25187265
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and molecular characterization of Thai patients with Wiskott-Aldrich syndrome.
    Amarinthnukrowh P; Ittiporn S; Tongkobpetch S; Chatchatee P; Sosothikul D; Shotelersuk V; Suphapeetiporn K
    Scand J Immunol; 2013 Jan; 77(1):69-74. PubMed ID: 23033889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Studies of the expression of the Wiskott-Aldrich syndrome protein.
    Stewart DM; Treiber-Held S; Kurman CC; Facchetti F; Notarangelo LD; Nelson DL
    J Clin Invest; 1996 Jun; 97(11):2627-34. PubMed ID: 8647957
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intermittent X-linked thrombocytopenia with a novel WAS gene mutation.
    Wada T; Itoh M; Maeba H; Toma T; Niida Y; Saikawa Y; Yachie A
    Pediatr Blood Cancer; 2014 Apr; 61(4):746-8. PubMed ID: 24115682
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gene therapy: primed for take-off.
    Leboulch P
    Nature; 2013 Aug; 500(7462):280-2. PubMed ID: 23955226
    [No Abstract]   [Full Text] [Related]  

  • 57. The Wiskott-Aldrich syndrome protein (WASP): roles in signaling and cytoskeletal organization.
    Snapper SB; Rosen FS
    Annu Rev Immunol; 1999; 17():905-29. PubMed ID: 10358777
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel mutation in Wiskott-Aldrich syndrome and successfully treated with umbilical cord blood transplantation.
    Zhu X; Tang B; Zheng C; Liu H; Song K; Sun Z
    Blood Cells Mol Dis; 2014 Dec; 53(4):283-5. PubMed ID: 24824128
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome.
    Bosticardo M; Marangoni F; Aiuti A; Villa A; Grazia Roncarolo M
    Blood; 2009 Jun; 113(25):6288-95. PubMed ID: 19351959
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients.
    Charrier S; Dupré L; Scaramuzza S; Jeanson-Leh L; Blundell MP; Danos O; Cattaneo F; Aiuti A; Eckenberg R; Thrasher AJ; Roncarolo MG; Galy A
    Gene Ther; 2007 Mar; 14(5):415-28. PubMed ID: 17051251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.